Janssen Biotech has entered into a worldwide collaboration and license agreement with Legend, a subsidary of Genscript Biotech Corporation. The partnership is to develop, manufacture and commercialize a chimeric antigen receptor (CAR) T-cell drug candidate, LCAR-B38M, which specifically targets the B-cell maturation antigen (BCMA).    LCAR-B38M is currently accepted for review by the China Food and Drug Administration (CFDA) and in the planning phase of clinical studies in the United Sta...